-+ 0.00%
-+ 0.00%
-+ 0.00%

BioNexus Q2 FY26 net loss narrows 53.51% to $286,451; revenue drops 96.63% to $76,156 vs year-ago quarter

PUBT·08/14/2026 21:07:51
Listen to the news
BioNexus Q2 FY26 net loss narrows 53.51% to $286,451; revenue drops 96.63% to $76,156 vs year-ago quarter
  • BioNexus Gene Lab posted a net loss attributable to common shareholders of USD 286,451, narrowing 53.51% year over year.
  • Revenue fell 96.63% to USD 76,156, reflecting a 96.65% drop at Chemrex to USD 75,506.
  • Operating loss narrowed to USD 282,396 from the prior-year quarter, while total gross profit slid to USD 12,982.
  • Cash and cash equivalents totaled USD 2.39 million at June 30, 2026; total liquidity was USD 3.5 million.
  • VitaGuard had not generated revenue as of June 30, 2026; GeneMatrix enterprise build completed internal workflow testing, targeting an initial Q3 2026 release.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNexus Gene Lab Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001477932-26-005093), on August 14, 2026, and is solely responsible for the information contained therein.